{
  "docId": "019de077-5130-7668-92cb-6c77396e6bd2",
  "docSlug": "e021a2de9332664c5094197b4bc248cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 157 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 115,
  "pageCount": 132,
  "prevPage": 114,
  "nextPage": 116,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a standard clinical trial registry format.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5130-7668-92cb-6c77396e6bd2/115",
  "deckHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2",
  "deckJsonHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2.json",
  "deckAnchorHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2#slide-115",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.18,
        "x": 0.79,
        "y": 0.06
      },
      "kind": "other",
      "text": "Early development",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23d044d5-0fd6-44a8-bb72-4ccb41b29a4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.95,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "table",
      "text": "Trial, Population, Patients, Design, Endpoints, Status. Phase I NCT05848440, Healthy volunteers, 64, SAD trial, Primary endpoint: safety and tolerability, FPCD: Q2 2023 LPCD: Q4 2023 Data readout: Q2 2024. Phase I CONTEMPO NCT06151964, Overweight and obese participants with T2DM, 90, Randomised, single-blind, placebo-controlled, MAD trial with 4 parts (A to D)..., Primary endpoints: safety and tolerability and PK parameters, FPCD: Q4 2023 Data anticipated: H2 2025",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "871e7198-0ee7-4c4d-acc3-bd0ce2bd426d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "AZD9550 (GLP-1-glucagon agonist) MASH",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1a48888-78c0-499c-bd4a-9832faccc043",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "d03c9d81-5cae-4a4d-a2b5-0e6b048412be",
      "evidence": "table/data: Trial, Population, Patients, Design, Endpoints, Status. Phase I NCT05848440, Healthy volunteers, 64, SAD trial, Primary endpoint: safety and tolerability, FPCD: Q2 2023 LPCD: Q4 2023 Data readout: Q2 2024. Ph",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 6,
      "beatId": "0c127c3c-ea10-450c-b057-64b7f7a0f03c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Detailed overview of AstraZeneca's pipeline and portfolio",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}